Gary Ingenito Joins Angiotech as Senior Vice President, Clinical Development and Regulatory Affairs
04 Februar 2005 - 3:00PM
PR Newswire (US)
Gary Ingenito Joins Angiotech as Senior Vice President, Clinical
Development and Regulatory Affairs VANCOUVER, Feb. 4
/PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:
ANPI; TSX: ANP), a specialty pharmaceutical company focused on
drug-eluting medical devices and biomaterials, today announced the
appointment of Gary Ingenito, MD, PhD to Senior Vice President,
Clinical Development & Regulatory Affairs, effective
immediately. Dr. Ingenito brings over 17 years of experience in
clinical and regulatory affairs having held executive positions in
large- and medium-sized pharmaceutical companies as well as
clinical research organizations. He joins the Company from SFBC
International, a major contract research organization acting as
Senior Vice President. Prior to joining SFBC, Dr. Ingenito was
Chief Operating Officer at Otsuka Maryland Research Institute of
Otsuka Pharmaceuticals where he was responsible for clinical and
regulatory strategy for programs involving the central nervous
system, cardiovascular, pulmonary, gastroenterology, endocrine and
ophthalmology. His position at Otsuka included extensive
involvement with the US Food and Drug Administration. Prior to
Otsuka, Dr. Ingenito held the position of Executive Director,
Clinical Research at Corning Besselaar overseeing the international
development of pharmaceuticals. He has also held senior positions
with Sandoz Pharmaceuticals focusing on strategic plans for
national and international clinical trials. Dr. Ingenito received a
PhD from Thomas Jefferson University, an MD from Jefferson Medical
College and a BA from Johns Hopkins University. He completed his
post-graduate residency at the University of Miami. "We are
thrilled with the addition of Dr. Ingenito to our management team,"
said William Hunter, MD, MSc, President and CEO of Angiotech. "He
brings a distinguished record of clinical development and
impressive knowledge of regulatory affairs that will be vital as we
execute on our pipeline and continue to revolutionize medical
device and biomaterial interventions." Dr. Ingenito will provide
strategic insight, leadership and direction for the company's
worldwide clinical development and regulatory activities.
Additional biographical detail on Angiotech's senior management is
available on the Company website at http://www.angiotech.com/.
Vancouver-based Angiotech Pharmaceuticals, Inc., a specialty
pharmaceutical company focusing on drug-eluting medical devices and
biomaterials, is dedicated to enhancing the performance of medical
devices and biomaterials through the innovative uses of
pharmacotherapeutics. To find out more about Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) please
visit our website at http://www.angiotech.com/ Statements contained
herein that are not based on historical or current fact, including
without limitation statements containing the words "anticipates,"
"believes," "may," "continue," "estimate," "expects," "may" and
"will" and words of similar import, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be
materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following:
general economic and business conditions, both nationally and in
the regions in which the Company operates; technology changes;
competition; changes in business strategy or development plans; the
ability to attract and retain qualified personnel; existing
governmental regulations and changes in, or the failure to comply
with, governmental regulations; liability and other claims asserted
against the Company; and other factors referenced in the Company's
filings with the United States Securities and Exchange Commission
or the Canadian securities regulators. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements. CONTACTS: Todd
Young, Angiotech Pharmaceuticals (Analysts & Investors), (604)
221-7676 ext 6933 Rui Avelar, Angiotech Pharmaceuticals, Inc.
(Analysts), (604) 221-7676 ext 6996 Eric Starkman, Starkman &
Associates (Media), (212) 252-8545 ext 12 DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Todd Young, Angiotech
Pharmaceuticals (Analysts & Investors), (604) 221-7676 ext
6933; Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts), (604)
221-7676 ext 6996; Eric Starkman, Starkman & Associates
(Media), (212) 252-8545 ext 12
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024